Contineum Therapeutics (CTNM) grants 206,411 options to general counsel

Rhea-AI Filing Summary

Contineum Therapeutics reported that its General Counsel and Corporate Secretary, John Stephen Healy, received a grant of stock options on January 30, 2026. The award covers 206,411 shares of Class A common stock at an exercise price of $14.26 per share.

The options were granted under the company’s 2024 Equity Incentive Plan and vest in equal monthly installments over 48 months, conditioned on Healy’s continued service with the company. Following this grant, he beneficially owns 206,411 stock options, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Healy John Stephen

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Corp Sec

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$14.26	01/30/2026		A		206,411		(1)	01/29/2036	Class A Common Stock	206,411	$0	206,411	D

Explanation of Responses:

1. Options granted under the Issuer's 2024 Equity Incentive Plan. The options shares vest in equal monthly installments over 48 months, subject to the Reporting Person's continuous service.

	/s/ Peter Slover, Attorney-in-Fact	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Contineum Therapeutics (CTNM) disclose in this Form 4 filing?

Contineum Therapeutics disclosed a stock option grant to officer John Stephen Healy. He received 206,411 options under the 2024 Equity Incentive Plan, vesting monthly over 48 months, contingent on his continued service with the company.

How many Contineum Therapeutics (CTNM) stock options were granted to John Stephen Healy?

John Stephen Healy was granted 206,411 stock options. These options give him the right to buy Class A common shares, vesting in equal monthly installments over 48 months, as long as he remains continuously employed or in service with the company.

What is the exercise price of the Contineum Therapeutics (CTNM) stock options granted?

The stock options were granted with an exercise price of $14.26 per share. This means Healy can purchase Class A common stock at $14.26 once the options vest, subject to the vesting schedule and his continued service with Contineum Therapeutics.

What is the vesting schedule for the Contineum Therapeutics (CTNM) options granted to Healy?

The options vest in equal monthly installments over 48 months. Vesting is conditioned on John Stephen Healy’s continuous service to Contineum Therapeutics, so he earns additional vested options each month during this four-year period.

How many Contineum Therapeutics (CTNM) derivative securities does Healy own after this transaction?

After the reported grant, Healy beneficially owns 206,411 derivative securities in the form of stock options. All are held directly and relate to Class A common stock, with vesting governed by the company’s 2024 Equity Incentive Plan terms.

Under which plan were the Contineum Therapeutics (CTNM) options to Healy granted?

The options were granted under Contineum Therapeutics’ 2024 Equity Incentive Plan. This plan governs equity awards, and in this case provides monthly vesting over 48 months, subject to John Stephen Healy maintaining continuous service with the company.